Skip to main content
Top
Published in: BMC Neurology 1/2014

Open Access 01-12-2014 | Research article

Early intervention in Alzheimer’s disease: a health economic study of the effects of diagnostic timing

Authors: Jennifer H Barnett, Lily Lewis, Andrew D Blackwell, Matthew Taylor

Published in: BMC Neurology | Issue 1/2014

Login to get access

Abstract

Background

Intervention and treatment in Alzheimer’s disease dementia (AD-dementia) can be cost effective but the majority of patients are not diagnosed in a timely manner. Technology is now available that can enable the earlier detection of cognitive loss associated with incipient dementia, offering the potential for earlier intervention in the UK health care system. This study aimed to determine to what extent the timing of an intervention affects its cost-effectiveness.

Methods

Using published data describing cognitive decline in the years prior to an AD diagnosis, we modelled the effects on healthcare costs and quality-adjusted life years of hypothetical symptomatic and disease-modifying interventions. Early and standard interventions were assumed to have equal clinical effects, but the early intervention could be applied up to eight years prior to standard diagnosis.

Results

A symptomatic treatment which immediately improved cognition by one MMSE point and reduced in efficacy over three years, would produce a maximum net benefit when applied at the earliest timepoint considered, i.e. eight years prior to standard diagnosis. In this scenario, the net benefit was reduced by around 17% for every year that intervention was delayed. In contrast, for a disease-modifying intervention which halted cognitive decline for one year, economic benefits would peak when treatment effects were applied two years prior to standard diagnosis. In these models, the maximum net benefit of the disease modifying intervention was fifteen times larger than that of the symptomatic treatment.

Conclusion

Timeliness of intervention is likely to have an important impact on the cost-effectiveness of both current and future treatments. Healthcare policy should aim to optimise the timing of AD-dementia diagnosis, which is likely to necessitate detecting and treating patients several years prior to current clinical practice.
Appendix
Available only for authorised users
Literature
1.
go back to reference Wimo A, Prince M: World Alzheimer Report 2010: The Global Economic Impact of Dementia. 2010, UK, London: Alzheimer’s Disease International Wimo A, Prince M: World Alzheimer Report 2010: The Global Economic Impact of Dementia. 2010, UK, London: Alzheimer’s Disease International
2.
go back to reference Prince M, Jackson J: World Alzheimer Report 2009. 2009, UK, London: Alzheimer’s Disease International Prince M, Jackson J: World Alzheimer Report 2009. 2009, UK, London: Alzheimer’s Disease International
3.
go back to reference Alzheimers Association: 2011 Alzheimer’s disease facts and figures. Alzheimers Dement. 2011, 7: 208-244.CrossRef Alzheimers Association: 2011 Alzheimer’s disease facts and figures. Alzheimers Dement. 2011, 7: 208-244.CrossRef
4.
go back to reference Ward A, Arrighi HM, Michels S, Cedarbaum JM: Mild cognitive impairment: disparity of incidence and prevalence estimates. Alzheimers Dement. 2012, 8: 14-21. 10.1016/j.jalz.2011.01.002.CrossRefPubMed Ward A, Arrighi HM, Michels S, Cedarbaum JM: Mild cognitive impairment: disparity of incidence and prevalence estimates. Alzheimers Dement. 2012, 8: 14-21. 10.1016/j.jalz.2011.01.002.CrossRefPubMed
5.
go back to reference Petersen RC: Mild Cognitive Impairment: Clinical Characterization and Outcome. Arch Neurol. 1999, 56: 303-308. 10.1001/archneur.56.3.303.CrossRefPubMed Petersen RC: Mild Cognitive Impairment: Clinical Characterization and Outcome. Arch Neurol. 1999, 56: 303-308. 10.1001/archneur.56.3.303.CrossRefPubMed
6.
go back to reference McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH: The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011, 7: 263-269. 10.1016/j.jalz.2011.03.005.CrossRefPubMedPubMedCentral McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH: The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011, 7: 263-269. 10.1016/j.jalz.2011.03.005.CrossRefPubMedPubMedCentral
7.
go back to reference Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH: The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011, 7: 270-279. 10.1016/j.jalz.2011.03.008.CrossRefPubMedPubMedCentral Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH: The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011, 7: 270-279. 10.1016/j.jalz.2011.03.008.CrossRefPubMedPubMedCentral
8.
go back to reference Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH: Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011, 7: 280-292. 10.1016/j.jalz.2011.03.003.CrossRefPubMedPubMedCentral Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH: Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011, 7: 280-292. 10.1016/j.jalz.2011.03.003.CrossRefPubMedPubMedCentral
9.
go back to reference Blennow K, Hampel H: CSF markers for incipient Alzheimer’s disease. Lancet Neurol. 2003, 2: 605-613. 10.1016/S1474-4422(03)00530-1.CrossRefPubMed Blennow K, Hampel H: CSF markers for incipient Alzheimer’s disease. Lancet Neurol. 2003, 2: 605-613. 10.1016/S1474-4422(03)00530-1.CrossRefPubMed
10.
go back to reference Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, Herholz K, Bokde ALW, Jessen F, Hoessler YC, Sanhai WR, Zetterberg H, Woodcock J, Blennow K: Biomarkers for Alzheimer’s disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov. 2010, 9: 560-574. 10.1038/nrd3115.CrossRefPubMed Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, Herholz K, Bokde ALW, Jessen F, Hoessler YC, Sanhai WR, Zetterberg H, Woodcock J, Blennow K: Biomarkers for Alzheimer’s disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov. 2010, 9: 560-574. 10.1038/nrd3115.CrossRefPubMed
11.
go back to reference Lorenzi M, Donohue M, Paternicò D, Scarpazza C, Ostrowitzki S, Blin O, Irving E, Frisoni GB: Enrichment through biomarkers in clinical trials of Alzheimer’s drugs in patients with mild cognitive impairment. Neurobiol Aging. 2010, 31: 1443-1451. 10.1016/j.neurobiolaging.2010.04.036. 1451.e1CrossRefPubMed Lorenzi M, Donohue M, Paternicò D, Scarpazza C, Ostrowitzki S, Blin O, Irving E, Frisoni GB: Enrichment through biomarkers in clinical trials of Alzheimer’s drugs in patients with mild cognitive impairment. Neurobiol Aging. 2010, 31: 1443-1451. 10.1016/j.neurobiolaging.2010.04.036. 1451.e1CrossRefPubMed
12.
go back to reference Blackwell AD, Sahakian BJ, Vesey R, Semple JM, Robbins TW, Hodges JR: Detecting dementia: novel neuropsychological markers of preclinical Alzheimer’s disease. Dement Geriatr Cogn Disord. 2004, 17: 42-48. 10.1159/000074081.CrossRefPubMed Blackwell AD, Sahakian BJ, Vesey R, Semple JM, Robbins TW, Hodges JR: Detecting dementia: novel neuropsychological markers of preclinical Alzheimer’s disease. Dement Geriatr Cogn Disord. 2004, 17: 42-48. 10.1159/000074081.CrossRefPubMed
14.
go back to reference Geldmacher DS: Cost-effectiveness of drug therapies for Alzheimer’s disease: A brief review. Neuropsychiatr Dis Treat. 2008, 4: 549-555.PubMedPubMedCentral Geldmacher DS: Cost-effectiveness of drug therapies for Alzheimer’s disease: A brief review. Neuropsychiatr Dis Treat. 2008, 4: 549-555.PubMedPubMedCentral
15.
go back to reference Getsios D, Blume S, Ishak KJ, Maclaine G, Hernández L: An economic evaluation of early assessment for Alzheimer’s disease in the United Kingdom. Alzheimers Dement. 2012, 8: 22-30. 10.1016/j.jalz.2010.07.001.CrossRefPubMed Getsios D, Blume S, Ishak KJ, Maclaine G, Hernández L: An economic evaluation of early assessment for Alzheimer’s disease in the United Kingdom. Alzheimers Dement. 2012, 8: 22-30. 10.1016/j.jalz.2010.07.001.CrossRefPubMed
16.
go back to reference Weimer DL, Sager MA: Early identification and treatment of Alzheimer’s disease: social and fiscal outcomes. Alzheimers Dement. 2009, 5: 215-226. 10.1016/j.jalz.2009.01.028.CrossRefPubMedPubMedCentral Weimer DL, Sager MA: Early identification and treatment of Alzheimer’s disease: social and fiscal outcomes. Alzheimers Dement. 2009, 5: 215-226. 10.1016/j.jalz.2009.01.028.CrossRefPubMedPubMedCentral
17.
go back to reference Alzheimer's Society: Mapping the Dementia Gap. 2012, UK, London: Alzheimer’s Society Alzheimer's Society: Mapping the Dementia Gap. 2012, UK, London: Alzheimer’s Society
18.
go back to reference Bradford A, Kunik ME, Schulz P, Williams SP, Singh H: Missed and delayed diagnosis of dementia in primary care: prevalence and contributing factors. Alzheimer Dis Assoc Disord. 2009, 23: 306-314. 10.1097/WAD.0b013e3181a6bebc.CrossRefPubMedPubMedCentral Bradford A, Kunik ME, Schulz P, Williams SP, Singh H: Missed and delayed diagnosis of dementia in primary care: prevalence and contributing factors. Alzheimer Dis Assoc Disord. 2009, 23: 306-314. 10.1097/WAD.0b013e3181a6bebc.CrossRefPubMedPubMedCentral
19.
go back to reference Song Y, Skinner J, Bynum J, Sutherland J, Wennberg JE, Fisher ES: Regional variations in diagnostic practices. N Engl J Med. 2010, 363: 45-53. 10.1056/NEJMsa0910881.CrossRefPubMedPubMedCentral Song Y, Skinner J, Bynum J, Sutherland J, Wennberg JE, Fisher ES: Regional variations in diagnostic practices. N Engl J Med. 2010, 363: 45-53. 10.1056/NEJMsa0910881.CrossRefPubMedPubMedCentral
20.
go back to reference Tricco AC, Soobiah C, Berliner S, Ho JM, Ng CH, Ashoor HM, Chen MH, Hemmelgarn B, Straus SE: Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis. CMAJ. 2013, 185: 1393-1401. 10.1503/cmaj.130451.CrossRefPubMedPubMedCentral Tricco AC, Soobiah C, Berliner S, Ho JM, Ng CH, Ashoor HM, Chen MH, Hemmelgarn B, Straus SE: Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis. CMAJ. 2013, 185: 1393-1401. 10.1503/cmaj.130451.CrossRefPubMedPubMedCentral
21.
go back to reference Lin P-J, Neumann PJ: The economics of mild cognitive impairment. Alzheimers Dement. 2013, 9: 58-62. 10.1016/j.jalz.2012.05.2117.CrossRefPubMed Lin P-J, Neumann PJ: The economics of mild cognitive impairment. Alzheimers Dement. 2013, 9: 58-62. 10.1016/j.jalz.2012.05.2117.CrossRefPubMed
22.
go back to reference Albert SM, Glied S, Andrews H, Stern Y, Mayeux R: Primary care expenditures before the onset of Alzheimer’s disease. Neurology. 2002, 59: 573-578. 10.1212/WNL.59.4.573.CrossRefPubMed Albert SM, Glied S, Andrews H, Stern Y, Mayeux R: Primary care expenditures before the onset of Alzheimer’s disease. Neurology. 2002, 59: 573-578. 10.1212/WNL.59.4.573.CrossRefPubMed
23.
go back to reference Cummings JL, Doody R, Clark C: Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology. 2007, 69: 1622-1634. 10.1212/01.wnl.0000295996.54210.69.CrossRefPubMed Cummings JL, Doody R, Clark C: Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology. 2007, 69: 1622-1634. 10.1212/01.wnl.0000295996.54210.69.CrossRefPubMed
24.
go back to reference Hogan DB, Bailey P, Black S, Carswell A, Chertkow H, Clarke B, Cohen C, Fisk JD, Forbes D, Man-Son-Hing M, Lanctôt K, Morgan D, Thorpe L: Diagnosis and treatment of dementia: 4. Approach to management of mild to moderate dementia. CMAJ. 2008, 179: 787-793. 10.1503/cmaj.070803.CrossRefPubMedPubMedCentral Hogan DB, Bailey P, Black S, Carswell A, Chertkow H, Clarke B, Cohen C, Fisk JD, Forbes D, Man-Son-Hing M, Lanctôt K, Morgan D, Thorpe L: Diagnosis and treatment of dementia: 4. Approach to management of mild to moderate dementia. CMAJ. 2008, 179: 787-793. 10.1503/cmaj.070803.CrossRefPubMedPubMedCentral
25.
go back to reference Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, Mohs RC, Thal LJ, Whitehouse PJ, DeKosky ST, Cummings JL: Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001, 56: 1154-1166. 10.1212/WNL.56.9.1154.CrossRefPubMed Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, Mohs RC, Thal LJ, Whitehouse PJ, DeKosky ST, Cummings JL: Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001, 56: 1154-1166. 10.1212/WNL.56.9.1154.CrossRefPubMed
26.
go back to reference Cooper C, Li R, Lyketsos C, Livingston G: Treatment for mild cognitive impairment: systematic review. Br J Psychiatry. 2013, 203: 255-264. 10.1192/bjp.bp.113.127811.CrossRefPubMedPubMedCentral Cooper C, Li R, Lyketsos C, Livingston G: Treatment for mild cognitive impairment: systematic review. Br J Psychiatry. 2013, 203: 255-264. 10.1192/bjp.bp.113.127811.CrossRefPubMedPubMedCentral
27.
go back to reference Amieva H, Jacqmin-Gadda H, Orgogozo J-M, Le Carret N, Helmer C, Letenneur L, Barberger-Gateau P, Fabrigoule C, Dartigues J-F: The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study. Brain. 2005, 128 (Pt 5): 1093-1101.CrossRefPubMed Amieva H, Jacqmin-Gadda H, Orgogozo J-M, Le Carret N, Helmer C, Letenneur L, Barberger-Gateau P, Fabrigoule C, Dartigues J-F: The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study. Brain. 2005, 128 (Pt 5): 1093-1101.CrossRefPubMed
28.
go back to reference Dartigues JF, Gagnon M, Barberger-Gateau P, Letenneur L, Commenges D, Sauvel C, Michel P, Salamon R: The Paquid epidemiological program on brain ageing. Neuroepidemiology. 1992, 11 (Suppl 1): 14-18.CrossRefPubMed Dartigues JF, Gagnon M, Barberger-Gateau P, Letenneur L, Commenges D, Sauvel C, Michel P, Salamon R: The Paquid epidemiological program on brain ageing. Neuroepidemiology. 1992, 11 (Suppl 1): 14-18.CrossRefPubMed
29.
go back to reference Folstein MF, Folstein SE, McHugh PR: “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975, 12: 189-198. 10.1016/0022-3956(75)90026-6.CrossRefPubMed Folstein MF, Folstein SE, McHugh PR: “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975, 12: 189-198. 10.1016/0022-3956(75)90026-6.CrossRefPubMed
30.
go back to reference Knapp M, Prince M: Dementia UK: A Report to the Alzheimer’s Society on the Prevalence and Economic Cost of of Dementia in the UK. 2007, London: Alzheimer's Society Knapp M, Prince M: Dementia UK: A Report to the Alzheimer’s Society on the Prevalence and Economic Cost of of Dementia in the UK. 2007, London: Alzheimer's Society
31.
go back to reference Curtis L: Unit Costs of Health and Social Care 2011. 2011, UK: Canterbury Curtis L: Unit Costs of Health and Social Care 2011. 2011, UK: Canterbury
32.
go back to reference Macdonald A, Cooper B: Long-term care and dementia services: an impending crisis. Age Ageing. 2007, 36: 16-22.CrossRefPubMed Macdonald A, Cooper B: Long-term care and dementia services: an impending crisis. Age Ageing. 2007, 36: 16-22.CrossRefPubMed
33.
go back to reference National Collaborating Centre for Mental Health: Dementia: A NICE-SCIE Guideline on Supporting People with Dementia and Their Carers in Health and Social Care. 2007, UK, London: The British Psychological Society National Collaborating Centre for Mental Health: Dementia: A NICE-SCIE Guideline on Supporting People with Dementia and Their Carers in Health and Social Care. 2007, UK, London: The British Psychological Society
34.
go back to reference Department of Health: NHS Reference Costs: Financial Year 2011 to 2012. 2012, UK, London: Department of Health Department of Health: NHS Reference Costs: Financial Year 2011 to 2012. 2012, UK, London: Department of Health
35.
go back to reference Jönsson L, Andreasen N, Kilander L, Soininen H, Waldemar G, Nygaard H, Winblad B, Jönhagen ME, Hallikainen M, Wimo A: Patient- and proxy-reported utility in Alzheimer disease using the EuroQoL. Alzheimer Dis Assoc Disord. 2006, 20: 49-55. 10.1097/01.wad.0000201851.52707.c9.CrossRefPubMed Jönsson L, Andreasen N, Kilander L, Soininen H, Waldemar G, Nygaard H, Winblad B, Jönhagen ME, Hallikainen M, Wimo A: Patient- and proxy-reported utility in Alzheimer disease using the EuroQoL. Alzheimer Dis Assoc Disord. 2006, 20: 49-55. 10.1097/01.wad.0000201851.52707.c9.CrossRefPubMed
37.
go back to reference Yiannopoulou KG, Papageorgiou SG: Current and future treatments for Alzheimer’s disease. Ther Adv Neurol Disord. 2013, 6: 19-33. 10.1177/1756285612461679.CrossRefPubMedPubMedCentral Yiannopoulou KG, Papageorgiou SG: Current and future treatments for Alzheimer’s disease. Ther Adv Neurol Disord. 2013, 6: 19-33. 10.1177/1756285612461679.CrossRefPubMedPubMedCentral
38.
go back to reference Sköldunger A, Johnell K, Winblad B, Wimo A: Mortality and treatment costs have a great impact on the cost-effectiveness of disease modifying treatment in Alzheimer’s disease–a simulation study. Curr Alzheimer Res. 2013, 10: 207-216. 10.2174/1567205011310020011.CrossRefPubMed Sköldunger A, Johnell K, Winblad B, Wimo A: Mortality and treatment costs have a great impact on the cost-effectiveness of disease modifying treatment in Alzheimer’s disease–a simulation study. Curr Alzheimer Res. 2013, 10: 207-216. 10.2174/1567205011310020011.CrossRefPubMed
39.
go back to reference Gervès C, Chauvin P, Bellanger MM: Evaluation of full costs of care for patients with Alzheimer’s disease in France: The predominant role of informal care. Health Policy. 2014, 116: 114-122. 10.1016/j.healthpol.2014.01.001.CrossRefPubMed Gervès C, Chauvin P, Bellanger MM: Evaluation of full costs of care for patients with Alzheimer’s disease in France: The predominant role of informal care. Health Policy. 2014, 116: 114-122. 10.1016/j.healthpol.2014.01.001.CrossRefPubMed
40.
go back to reference Gillespie P, O’Shea E, Cullinan J, Lacey L, Gallagher D, Ni Mhaolain A: The effects of dependence and function on costs of care for Alzheimer’s disease and mild cognitive impairment in Ireland. Int J Geriatr Psychiatry. 2013, 28: 256-264. 10.1002/gps.3819.CrossRefPubMed Gillespie P, O’Shea E, Cullinan J, Lacey L, Gallagher D, Ni Mhaolain A: The effects of dependence and function on costs of care for Alzheimer’s disease and mild cognitive impairment in Ireland. Int J Geriatr Psychiatry. 2013, 28: 256-264. 10.1002/gps.3819.CrossRefPubMed
41.
go back to reference Schneider N, Yvon C: A review of multidomain interventions to support healthy cognitive ageing. J Nutr Health Aging. 2013, 17: 252-257. 10.1007/s12603-012-0402-8.CrossRefPubMed Schneider N, Yvon C: A review of multidomain interventions to support healthy cognitive ageing. J Nutr Health Aging. 2013, 17: 252-257. 10.1007/s12603-012-0402-8.CrossRefPubMed
42.
go back to reference Gustavsson A, Brinck P, Bergvall N, Kolasa K, Wimo A, Winblad B, Jönsson L: Predictors of costs of care in Alzheimer’s disease: a multinational sample of 1222 patients. Alzheimers Dement. 2011, 7: 318-327. 10.1016/j.jalz.2010.09.001.CrossRefPubMed Gustavsson A, Brinck P, Bergvall N, Kolasa K, Wimo A, Winblad B, Jönsson L: Predictors of costs of care in Alzheimer’s disease: a multinational sample of 1222 patients. Alzheimers Dement. 2011, 7: 318-327. 10.1016/j.jalz.2010.09.001.CrossRefPubMed
Metadata
Title
Early intervention in Alzheimer’s disease: a health economic study of the effects of diagnostic timing
Authors
Jennifer H Barnett
Lily Lewis
Andrew D Blackwell
Matthew Taylor
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2014
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/1471-2377-14-101

Other articles of this Issue 1/2014

BMC Neurology 1/2014 Go to the issue